1.EFFECT OF PHYTIC ACID ON COLORECTAL CARCINOGENESIS AND NATURAL KILLER CELL ACTIVITY IN RATS
Zheng ZHANG ; Yang SONG ; Ketao LAN
Acta Nutrimenta Sinica 1956;0(04):-
Objective: To study the effect of phytic acid (PHA) on 1,2-dimethylhydrazine (DMH) induced colorectal carcinogenesis in rats. Methods: Thirty four weeks old healthy male Wistar rats were randomly divided into two groups,control group given basal diet and PHA group given basal diet plus 2% sodium phytate solution. Both groups were injected DMH weekly for 20 w and then killed . Body weight, mortality, tumour incidence and average size, and natural killer(NK)cell activity were measured. Result: The mortality was lower in PHA group (P
2. Clinicopathologic and prognosis features of Claudin-low breast cancers
Jing XU ; Ketao LAN ; Tianhui SU ; Zhenfeng LI ; Yue WAN ; Qinqin GU ; Pengcheng ZOU ; Xiao ZOU
Chinese Journal of Pathology 2017;46(9):634-639
Objective:
To investigate the clinicopathologic and prognostic features of Claudin-low breast cancers (CLBC).
Methods:
Tissue microarray sections were scored semiquantitatively for the immunohistochemical expression of claudin-1, -3, -4, -7 and -8 in 233 cases of invasive breast cancers collected from Qingdao Central Hospital from January 2010 to December 2011.
Results:
The expression rate of Claudin-3 (72/212, 33.9%) and -4 (56/212, 45.2%) was most similar, and Claudin-4 showed the highest expression. Twenty one cases (21/212, 9.0%) were diagnosed as CLBC, with triple-negative breast cancer (TNBC) accounted for the highest proportion (11/21, 52.4%). Among the CLBC cases, the invasive carcinoma no special type (66.7%, 14/21) and metaplastic carcinoma (14.3%, 3/21) were mostly seen, while metaplastic squamous carcinoma did not show Claudin-low pattern. Compared to the non CLBC in this cohort, CLBC had higher proportion of histologic grade 3 and tumors larger than 2 cm, and the proportions were slightly lower than TNBC. Patients with CLBC had lower 5 year disease-free(
3.Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
Youxin JI ; Zhongfa ZHANG ; Keke NIE ; Ketao LAN ; Chuanxin GENG ; Shichao LIU ; Ling ZHANG ; Zongchun ZHANG ; Lei SUN ; Xiao ZOU
Chinese Medical Journal 2014;127(8):1600-1600